MedTrace Logo

Clinical Trial Assessing the Efficacy and Safety of Hépar® in Chronic Constipation

NCT03348007 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 262

Last updated 2017-11-27

No results posted yet for this study

Summary

The study objectives are to evaluate the efficacy and safety of a 2-week daily intake of 1L Hépar® natural mineral water rich in magnesium sulphate compared to a control natural mineral water in the treatment of the constipation symptoms in women outpatients.

Conditions

  • Constipation - Functional

Interventions

OTHER

Taking two kinds of mineral water

1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).

Sponsors & Collaborators

  • Quanta Medical

    lead INDUSTRY

Principal Investigators

  • Baudouin TCHAKONTE, MD · 44340 Bouguenais France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-30
Primary Completion
2016-07-22
Completion
2016-07-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03348007 on ClinicalTrials.gov